RecruitingNCT06717594
PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE
PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to Carbapenem-resistant Enterobacterales (CRE)
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment
60 participants
Start Date
Dec 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
A multicenter international prospective observational pharmacological study in adult patients (≥18 years) treated with ceftazidime/avibactam (CAZ/AVI) alone or with CAZ/AVI plus fosfomycin (FOS) for infection due to carbapenem-resistant Enterobacterales (CRE) (KPC and/or OXA-48).
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Signature of the informed consent
- Age ≥ 18 years
- Adult patients treated for ≥ 48 hours with CAZ/AVI or CAZ/AVI plus FOS for a microbiologically documented CRE infection
Exclusion Criteria1
- Polymicrobial/mixed infections with exception of cases with multiple Enterobacterales susceptible to study drugs
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06717594
Related Trials
The Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome (ACT-FAST)
NCT074914191 location
A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections
NCT0682884822 locations
Antibiotic Duration and Outcomes in High-Risk Febrile Neutropenia Patients
NCT073721311 location
A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections
NCT070630951 location
NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria
NCT050177661 location